Samsara BioCapital, LLC — 13F Holdings & Portfolio
CIK 1744967 · latest 13F-HR filed 2026-08-14
Samsara BioCapital, LLC manages $1.22B in 13F-reported U.S. long-equity assets across 24 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are SRRK (31.16%), ALMS (14.67%), MLYS (13.01%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions, exited 2, added to 10, and trimmed 8.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
PALO ALTO, CA 94301
$1.22B
Long-equity book
24
Distinct positions
2026-06-30
Filed 2026-08-14
+4 / −2 / ↑10 / ↓8
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- SCHOLAR ROCK HLDG CORP$40.3M +11.9%
- ALUMIS INC$38.8M +27.7%
- SEPTERNA INC$29.8M +39.4%
- NEUROGENE INC$19.4M +56.0%
- SUTRO BIOPHARMA INC$8.8M +33.3%
Top Trims
- KALARIS THERAPEUTICS INC-$22.3M -29.8%
- SPYGLASS PHARMA INC-$7.7M -14.1%
- INVENTIVA SA-$5.0M -17.2%
- UPSTREAM BIO INC-$4.2M -63.1%
- GOSSAMER BIO INC-$1.2M -49.9%
New Positions
- ALAMAR BIOSCIENCES INC$67.2M
- PARABILIS MEDICINES INC$15.2M
- ARTIVA BIOTHERAPEUTICS INC$9.3M
- ELOXX PHARMACEUTICALS INC$5.6M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $379.4M | 31.16% | 6,897,652 | SH |
| 2 | ALUMIS INC | ALMS | 022307102 | $178.6M | 14.67% | 6,345,219 | SH |
| 3 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $158.4M | 13.01% | 5,871,018 | SH |
| 4 | SEPTERNA INC | SEPN | 81734D104 | $105.5M | 8.66% | 3,149,128 | SH |
| 5 | ALAMAR BIOSCIENCES INC | ALMR | 010911105 | $67.2M | 5.52% | 2,480,310 | SH |
| 6 | NEUROGENE INC | NGNE | 64135M105 | $54.0M | 4.44% | 1,717,127 | SH |
| 7 | KALARIS THERAPEUTICS INC | KLRS | 482929106 | $52.4M | 4.31% | 12,881,175 | SH |
| 8 | SPYGLASS PHARMA INC | SGP | 85220G109 | $47.0M | 3.86% | 2,109,953 | SH |
| 9 | SUTRO BIOPHARMA INC | STRO | 869367201 | $35.3M | 2.90% | 1,062,872 | SH |
| 10 | INVENTIVA SA | IVA | 46124U107 | $23.9M | 1.96% | 6,314,805 | SH |
| 11 | JADE BIOSCIENCES INC | JBIO | 008064206 | $16.4M | 1.34% | 736,237 | SH |
| 12 | PARABILIS MEDICINES INC | PBLS | 698955101 | $15.2M | 1.25% | 556,044 | SH |
| 13 | VTV THERAPEUTICS INC | VTVT | 918385204 | $11.2M | 0.92% | 298,496 | SH |
| 14 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $10.4M | 0.85% | 2,500,000 | SH |
| 15 | NKARTA INC | NKTX | 65487U108 | $9.9M | 0.82% | 3,507,666 | SH |
| 16 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $9.3M | 0.76% | 954,861 | SH |
| 17 | RANI THERAPEUTICS HLDGS INC | RANI | 753018100 | $7.9M | 0.65% | 10,369,159 | SH |
| 18 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $7.8M | 0.64% | 600,000 | SH |
| 19 | ABIVAX SA | ABVX | 00370M103 | $7.3M | 0.60% | 55,095 | SH |
| 20 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $6.5M | 0.54% | 1,395,587 | SH |
| 21 | ELOXX PHARMACEUTICALS INC | ELOX | 29014R301 | $5.6M | 0.46% | 400,000 | SH |
| 22 | COHERUS ONCOLOGY INC | CHRS | 19249H103 | $4.8M | 0.39% | 3,428,571 | SH |
| 23 | UPSTREAM BIO INC | UPB | 91678A107 | $2.4M | 0.20% | 353,717 | SH |
| 24 | GOSSAMER BIO INC | GOSS | 38341P102 | $1.2M | 0.10% | 7,222,559 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.22B | 24 | 0001744967-26-000010 |
| 2026-03-31 | 2026-05-15 | $1.03B | 22 | 0001744967-26-000005 |
| 2025-12-31 | 2026-02-17 | $969.3M | 21 | 0001744967-26-000002 |
| 2025-09-30 | 2025-11-14 | $765.9M | 27 | 0001744967-25-000004 |